EN DE
Watch Adagene Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Adagene Inc (ADAG) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Adagene Inc stock $1.40, price $1.60, that is 12.5% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in China

AI Adagene Inc logo Thin data Nov 16, 2026

Adagene Inc

ADAG · US

Expensive (fair value 13% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Ranks above peers (5/8) 
Revenue last quarter +73% vs. a year ago. 
Quality 40/100 
Insiders bought $162,258 (6M) 
Fair value $1.40 · Overvalued 
Weak Growth (revenue 3y −6.2 %/yr in USD) 
Negative free cash flow 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Adagene Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$18.55 $0.9000 Fair Value $1.40 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range $0.9000 – $18.55 · fair‑value band $1.05 – $1.75 · the $1.60 price screens above the $1.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Adagene in your weekly email

Every Wednesday you see whether Adagene is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China.

Show moreShow less

Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.

The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development.

In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors.

Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Stock analysis

Adagene Inc (ADAG) currently trades at $1.60, while our estimate is $1.40, 13% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.05 (bear) to $1.75 (bull), the price of $1.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Adagene Inc reported revenue of $7.7M in FY2025 versus $10.2M in FY2021, a compound −6.8%/yr. Reported net income was −$17.6M in FY2025.

Key figures

Market cap $162M Micro · P/S ratio 17.4 · EPS (TTM) $−0.3800 · Return on equity −28.5% · Return on assets (EBIT) −36.3% (5-year average) · Operating margin −1,024% · Revenue (TTM) $9.3M · Revenue growth (YoY) +73.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 67% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −13%, ADAG screens richer than that median.

Fair Value

Bear $1.05 Fair Value $1.40 Bull $1.75
Price $1.60 · Downside -12.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 64
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 44
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 12
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors bought shares worth $162,258, most recently on Sep 23, 2026. Buying cluster

  • BuyMan Kin TamChief Financial Officer, Director2,000 shares at $3.00$6,000Sep 23, 2026
  • BuyPeter LuoChief Executive Officer, Director2× since Aug 4, 2026: 43,535 shares, avg. $3.42$148,758Sep 16, 2026
  • BuyCuong Do VDirector2,000 shares at $3.75$7,500Aug 14, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+74.1%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,993.7% (2020) → −279.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ADAG screens overvalued: fair value 13% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Adagene Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 40 · Above median
Fair Value upside −12.5% · Above median
Profitability
Return on assets −22.5% · Below median
Growth and dividend
Revenue growth (quarter YoY) 73.3% · Top 25%
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.58× · Pricier than median
P/S (12 months) 17.42× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)17 · sector 1
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs ADAG
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs ADAG
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs ADAG
argenx SE ARGX $950.95 $908.40 −4% vs ADAG
CSL Limited CSL A$199.55 A$186.49 −7% vs ADAG
Moderna, Inc MRNA $215.27 $135.64 −37% vs ADAG
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs ADAG
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs ADAG
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs ADAG
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs ADAG

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Adagene Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Adagene Inc Fair Value". https://www.fairvalue-calculator.com/stock/ADAG

Frequently asked questions

Is Adagene Inc (ADAG) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is $1.40 versus a price of $1.60, about 13% lower (overvalued).
What is the fair value of ADAG?
Our estimate for Adagene Inc is $1.40 (as of Nov 16, 2026), built from audited fundamentals. The current price: $1.60.
What is the quality score of ADAG?
Adagene Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Adagene Inc (ADAG)?
Our calculated price target is the estimate of $1.40 (as of Nov 16, 2026). Cautious scenario $1.05, optimistic scenario $1.75. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Adagene Inc stock forecast for 2026?
Our estimate puts fair value at $1.40, about 13% lower versus a price of $1.60 (overvalued). Cautious scenario $1.05, optimistic scenario $1.75. The calculation is refreshed regularly with new filings.
What is the revenue of Adagene Inc (ADAG)?
Adagene Inc reported trailing-twelve-month revenue of about $9.3M (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Adagene Inc (ADAG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Adagene Inc it is $1.40 per share (as of Nov 16, 2026), against a price of $1.60.
Is Adagene Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, ADAG trades above its calculated fair value: price $1.60, fair value $1.40, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ADAG?
No. The price is what the market pays today ($1.60); the fair value is what the company's own numbers justify ($1.40). For Adagene Inc the two are $0.2000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Adagene Inc worth?
The market values Adagene Inc at about $162M (market capitalisation, as of Nov 16, 2026). Per share that is $1.60; our models calculate a fair value of $1.40 per share.
What do the bullish and bearish scenarios say about ADAG?
Our models span a range for Adagene Inc: cautious scenario $1.05, base $1.40, optimistic $1.75 per share (as of Nov 16, 2026, price $1.60). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Adagene Inc (ADAG)?
Balance-sheet figures for Adagene Inc (as of Nov 16, 2026): return on equity −28.5%, debt of 0.03 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is ADAG from its 52-week high?
Adagene Inc trades at $1.60, about 67% below its 52-week high of $4.78 and 5% above the low of $1.53 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $1.40 is for.
Which stocks are comparable to Adagene Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Adagene Inc stock attractive at the current price?
The data as of Nov 16, 2026: price $1.60, calculated fair value $1.40 (−13%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Adagene Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Adagene Inc (ADAG)?
The closing price on Nov 16, 2026 was $1.60. Our estimate is $1.40, about 13% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Adagene Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Adagene Inc

How large is the market capitalisation of Adagene Inc (ADAG)?
The market capitalisation of Adagene Inc is $162M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Adagene Inc (ADAG)?
The price-to-sales ratio of Adagene Inc is 17.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Adagene Inc (ADAG)?
Earnings per share at Adagene Inc are $−0.3800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Adagene Inc (ADAG)?
The return on equity (ROE) of Adagene Inc is −28.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Adagene Inc (ADAG)?
On an EBIT basis the return on assets of Adagene Inc is −36.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Adagene Inc (ADAG)?
The operating margin of Adagene Inc is −1,024% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Adagene Inc (ADAG)?
Revenue at Adagene Inc is growing 73.3% versus a year earlier (3y avg −6.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Adagene Inc (ADAG) generate?
The free cash flow of Adagene Inc is −$15.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Adagene Inc (ADAG) hold?
Adagene Inc holds more cash than debt, $68.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Adagene Inc in the live analysis

One click puts Adagene Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.